Fig. 5

The effects of rapamycin on tumour growth and on oncometabolite production in vivo. Growth curve of the tumour (a.), and the measured tumour weights (b.), lactate (c.) and 2-HG (d.) levels of control and Rapamune (3 mg/kg, 3 weeks) treated HT-1080 xenografts (LC-MS, n = 6,*:p < 0.05; metabolite levels in nmol/10 mg tumour mass were given